Services and expertise in Personalized Tumor Therapy: from molecular analysis to personalized therapy

Currently, one in four deaths is caused by cancer – mainly as a result of metastatic disease spread. The focus of this Fraunhofer ITEM division, therefore, is on the development of diagnostic tests to enable detection of disseminated cancer cells early in the disease and prediction of the response to therapy of metastatic progenitor cells. Since the currently available therapies are effective only in one in four cancer patients, we aim to develop novel targeted systemic treatment options.

Services and expertise

 

Single-cell analytics

 

Mathematical modeling and bioinformatics

 

Innovative tumor models

Our Division of Personalized Tumor Therapy is ISO 9001-certified

ITEM is DIN ISO 9001:2015 certified

The Fraunhofer ITEM Division of Personalized Tumor Therapy, based in Regensburg (Germany), has been certified by TÜV SÜD according to DIN ISO 9001:2015 and thus complies with international requirements. The independent technical service corporation TÜV SÜD will perform routine inspection of structures, workflows, and processes in our division. This provides the following benefits for ourselves and our clients:

  • Sustainable quality management
  • Minimization of risks
  • Worldwide comparability
  • Continued optimization of processes
  • Early recognition of possible improvements
  • Fulfillment of special customer requirements
  • Higher client and employee satisfaction

The quality management standard ISO 9001 is the most widely established and most relevant quality management standard, both nationally and internationally.

Contact

Christoph Andreas Klein

Contact Press / Media

Prof. Dr. Christoph Andreas Klein

Division Director of Personalized Tumor Therapy

Phone +49 941 298480-21

  • Send email
Bernhard Michael Polzer

Contact Press / Media

Dr. Bernhard Michael Polzer

Manager of the Working Group on Cellular and Molecular Diagnostics

Phone +49 941 298480-23